Queen Mary Utilization Of Antihypertensive Drugs Study: Use of antihypertensive drug classes in the Hypertension Clinic 1996-2004

British Journal of Clinical Pharmacology

Volumn 60, Issue 1, 2005, Pages 90-97

  Cheung, Bernard M Y ^a,d   Wong, Yuk Lin ^b,c   Lau, Chu Pak ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SUNDERLAND   (United Kingdom)

^d QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

blocker; Angiotensin converting enzyme inhibitor; Calcium channel blocker; Drug utilization; Hypertension; Thiazide diuretic

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; METFORMIN; METHYLDOPA; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; FEMALE; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 21744449230     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02388.x     Document Type: Review

References (34)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
2. Cheung BMY, Law FCY, Lau CP. The rule of halves applies in Chinese hypertensive patients. Am J Hypertens 2002; 15: 209A.
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955-64.
4. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.
5. Cheung BMY, Cheung AHK, Ho SPC, Lau CP, Kumana CR. Utilisation of antihypertensive drugs in a hypertension clinic in 1996 and 1998. J Clin Pharmacol 1999; 39: 969.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317: 703-13.
7. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641-50.
8. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt Q, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757-64.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 51: 1755-62.
10. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester P-O, Hedner T, de Faire U, for the STOP-Hypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
11. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers C, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
16. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings CL, Johnston CI, McNeil JJ, Macdonald CJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92.
17. Pitt B, Segal R, Martinez FA, Meurers C, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747-52.
18. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
19. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
21. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
22. Whitworth JA; World Health Organization International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
23. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
24. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 2004; 291: 54-62.
25. Chou CC, Lee MS, Ke CH, Chung MH. Prescription patterns of hypertension-National Health Insurance in Taiwan. J Chin Med Assoc 2004; 67: 123-30.
26. Cheung BMY, Lam TH, Lam KSL, Tam SCF, Wat NMS, Man YB, Cheng CH, Kumana CR, Lau CP. The Hong Kong Cardiovascular Risk Factor Prevalence Survey cohort-results at 7 years. J Hypertens 2004; 22 (Suppl. 2): S268-9.
27. Cheung BMY, Lau CP, Kumana CR. Combination therapy for hypertension. Hong Kong Med J 2003; 9: 224-6.
28. Woo KS, Norris RM, Nicholls C. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995; 75: 967-8.
29. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356 (9246): 1949-54.
30. Lau CP, Cheung BMY. Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomised double-blind study. J Cardiovasc Pharmacol 1996; 28: 328-31.
31. Cheung BMY, Lau CP, Wu BZ. Efficacy and tolerability of three new dihydropyridine calcium channel blockers: amlodipine, felodipine and isradipine. Clin Ther 1998; 20: 1159-69.
32. Cheung BMY, Law FCY, Tam SCF, Kumana CR, Lau CP. Plasma renin activity and aldosterone level in patients with essential hypertension. Am J Hypertens 2002; 15: 210A.
33. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13.
34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thorn SMcG; British Hypertension Society. Guidelines for management of hypertension: Report of the fourth Working Party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-85.